CD4 and Hepatic fibrosis: Nonetheless, the French group confirmed that a high value of CD4+ cells at baseline was more frequent in patients undergoing regression of liver fibrosis, and highlighted that the duration of cART (in particular, treatments containing protease inhibitors [PIs]), was significantly associated with progression to a severe stage of F3-F4 fibrosis in patients with a METAVIR score at baseline of F0, F1 or F2 (OR 1.07, CI 95% 1.00–1.15 and OR 2.41, CI 95% 1.38–4.19, respectively) [43].